KLHL12 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Velcade (Bortezomib) is a proteasome inhibitor that can functionally inhibit KLHL12 by preventing the degradation of proteins that are negatively regulated by KLHL12-mediated ubiquitination. By inhibiting the proteasome, Velcade may lead to the accumulation of such substrates, which could sequester KLHL12 and limit its ability to further ubiquitinate other substrate proteins. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor similar to Velcade. It can inhibit the degradation of proteins targeted by KLHL12, potentially leading to an accumulation of KLHL12 substrates that may sequester KLHL12, thereby inhibiting its function indirectly. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By preventing the proteasomal degradation of proteins ubiquitinated by KLHL12, it can lead to an indirect inhibition of KLHL12 by allowing its substrates to accumulate and possibly sequester the protein. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that can increase the levels of KLHL12 substrates in the cell, which may bind to and sequester KLHL12, indirectly inhibiting its function. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
MLN2238, also known as Ixazomib, is a proteasome inhibitor. It can indirectly inhibit KLHL12 by stabilizing its substrates, which could compete with new substrates for binding to KLHL12, thus functionally inhibiting its activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor, which can lead to the accumulation of KLHL12 substrates, indirectly inhibiting the protein by preventing it from interacting with and ubiquitinating new substrates. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that can indirectly inhibit KLHL12 by causing the accumulation of proteins that are normally ubiquitinated and degraded by the proteasome, potentially sequestering KLHL12 and inhibiting its ubiquitination function. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can lead to the build-up of KLHL12 substrates within the cell, which may indirectly inhibit KLHL12 by sequestering it and preventing it from ubiquitinating other substrate proteins. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX 0914, also known as PR-957, is an immunoproteasome inhibitor that can indirectly inhibit KLHL12 by stabilizing its substrates, leading to their accumulation, which could sequester KLHL12 and inhibit its function. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin is an inhibitor of the enzyme thioredoxin reductase. By altering the cellular redox state, it may indirectly affect the function of KLHL12, as redox changes can influence protein interactions and stability, potentially leading to the functional inhibition of KLHL12 by affecting its ability to ubiquitinate substrates. | ||||||